Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-Current Deferred Tax Liability (2018 - 2025)

Sangamo Therapeutics has reported Non-Current Deferred Tax Liability over the past 9 years, most recently at $15000.0 for Q1 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at $15000.0 for Q1 2025, changed N/A from a year ago — trailing twelve months through Mar 2025 was $15000.0 (changed N/A YoY), and the annual figure for FY2022 was $28.1 million, up 323.36%.
  • Non-Current Deferred Tax Liability for Q1 2025 was $15000.0 at Sangamo Therapeutics, down from $6.4 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for SGMO hit a ceiling of $28.1 million in Q4 2022 and a floor of $15000.0 in Q1 2025.
  • Median Non-Current Deferred Tax Liability over the past 4 years was $6.6 million (2021), compared with a mean of $8.0 million.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: tumbled 79.12% in 2021 and later surged 323.36% in 2022.
  • Sangamo Therapeutics' Non-Current Deferred Tax Liability stood at $6.6 million in 2021, then skyrocketed by 323.36% to $28.1 million in 2022, then tumbled by 77.35% to $6.4 million in 2023, then plummeted by 99.76% to $15000.0 in 2025.
  • The last three reported values for Non-Current Deferred Tax Liability were $15000.0 (Q1 2025), $6.4 million (Q1 2023), and $28.1 million (Q4 2022) per Business Quant data.